JP2011527666A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527666A5
JP2011527666A5 JP2011507512A JP2011507512A JP2011527666A5 JP 2011527666 A5 JP2011527666 A5 JP 2011527666A5 JP 2011507512 A JP2011507512 A JP 2011507512A JP 2011507512 A JP2011507512 A JP 2011507512A JP 2011527666 A5 JP2011527666 A5 JP 2011527666A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound according
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011507512A
Other languages
English (en)
Japanese (ja)
Other versions
JP5442717B2 (ja
JP2011527666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/039065 external-priority patent/WO2009134574A2/en
Publication of JP2011527666A publication Critical patent/JP2011527666A/ja
Publication of JP2011527666A5 publication Critical patent/JP2011527666A5/ja
Application granted granted Critical
Publication of JP5442717B2 publication Critical patent/JP5442717B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011507512A 2008-04-29 2009-04-01 二置換フタラジンヘッジホッグ経路アンタゴニスト Expired - Fee Related JP5442717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29
US61/048,729 2008-04-29
PCT/US2009/039065 WO2009134574A2 (en) 2008-04-29 2009-04-01 Disubstituted phthalazine hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2011527666A JP2011527666A (ja) 2011-11-04
JP2011527666A5 true JP2011527666A5 (enExample) 2013-05-23
JP5442717B2 JP5442717B2 (ja) 2014-03-12

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507512A Expired - Fee Related JP5442717B2 (ja) 2008-04-29 2009-04-01 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (22)

Country Link
US (1) US7981892B2 (enExample)
EP (1) EP2294061A2 (enExample)
JP (1) JP5442717B2 (enExample)
KR (1) KR101260116B1 (enExample)
CN (1) CN102066353B (enExample)
AU (1) AU2009241561B2 (enExample)
BR (1) BRPI0911618A2 (enExample)
CA (1) CA2723042A1 (enExample)
CO (1) CO6300945A2 (enExample)
CR (1) CR11741A (enExample)
DO (1) DOP2010000302A (enExample)
EA (1) EA201071248A1 (enExample)
EC (1) ECSP10010577A (enExample)
HN (1) HN2010002157A (enExample)
IL (1) IL208211A0 (enExample)
MA (1) MA32349B1 (enExample)
MX (1) MX2010011948A (enExample)
MY (1) MY159491A (enExample)
NZ (1) NZ588001A (enExample)
UA (1) UA102250C2 (enExample)
WO (1) WO2009134574A2 (enExample)
ZA (1) ZA201006695B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
AU2009320251C1 (en) * 2008-11-03 2013-08-15 Eli Lilly And Company Disubstituted phthalazine Hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
US8445493B2 (en) * 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US20120232087A1 (en) * 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CA2878082A1 (en) 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
KR20230107568A (ko) 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법
CN119907797A (zh) * 2022-09-23 2025-04-29 默沙东有限责任公司 用作nod样受体蛋白3抑制剂的酞嗪衍生物
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
CN1104430C (zh) 1996-01-15 2003-04-02 詹森药业有限公司 抑制血管生成的哒嗪胺
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2000074706A1 (en) 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
EP1789390B1 (en) * 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
NZ579402A (en) * 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
AU2008269128B2 (en) * 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
ES2392157T3 (es) 2007-09-07 2012-12-05 Amgen Inc. Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009320251C1 (en) 2008-11-03 2013-08-15 Eli Lilly And Company Disubstituted phthalazine Hedgehog pathway antagonists
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2011527666A5 (enExample)
JP2012530705A5 (enExample)
JP2012507535A5 (enExample)
JP2010523692A5 (enExample)
JP2012509265A5 (enExample)
JP2010518090A5 (enExample)
JP2014507464A5 (enExample)
NZ591945A (en) Disubstituted phthalazine hedgehog pathway antagonists
JP2014508811A5 (enExample)
JP2012509263A5 (enExample)
JP2009535462A5 (enExample)
JP2010520214A5 (enExample)
JP2008044952A5 (enExample)
JP2013502441A5 (enExample)
JP2013522292A5 (enExample)
JP2011529054A5 (enExample)
JP2017528475A5 (enExample)
JP2010511721A5 (enExample)
JP2012526168A5 (enExample)
JP2011513410A5 (enExample)
JP2014526533A5 (enExample)
JP2013544854A5 (enExample)
JP2011190277A5 (enExample)
JP2009184932A5 (enExample)
JP2010507590A5 (enExample)